BCTX
BriaCell Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · CA
$3.19
+5.98%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -0.8%
- EBIT
- -3.8%
- EPS
- +77.1%
- Free cash flow
- +19.2%
- Operating cash flow
- +19.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +5.7%
- EBIT
- +5.6%
- Net income
- +4.4%
- EPS
- +88.9%
- Free cash flow
- +26.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026